semaglutide life extension Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial - Wilding - 2022 - Diabetes, Obesity and Metabolism US, Japan Patients With Diabetes
Description
Round up for priming losses, dropped syringes, damaged swabs, and any protocol adjustments
GLP-1 medications may increase SIBO risk because slowed gastric emptying can alter the normal flow patterns that keep bacteria where they belong
As of 2026, retatrutide is not approved for any indication by any regulator anywhere in the world
The goal isnt just short-term loss but sustainable health improvement
